The significant increase in R&D spending and substantial 2026 guidance suggests the company is aggressively advancing its clinical pipeline, particularly with multiple Phase 3 trials. Traders should monitor upcoming clinical readouts, especially the RASolute 302 trial in pancreatic cancer expected in 1H 2026, as key value inflection points.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $102.15entry
- T+1 · 9mo ago −0.13%α +0.35% · $102.02
- T+5 · 9mo ago −2.46%α −1.30% · $99.64
- T+20 · 8mo ago −8.75%α −2.34% · $93.21
- T+60 · 6mo ago +48.37%α +40.20% · $151.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines reported its 2025 financial results, highlighting a $1.1 billion net loss on $987.3 million in R&D expenses as it advances a broad late-stage oncology pipeline. The company maintains a strong $2.0 billion cash position and provided 2026 operating expense guidance of $1.6-$1.7 billion, reflecting continued heavy investment in clinical development.
Key Financial Metrics
Key Facts
- Cash, cash equivalents and marketable securities were $2.0 billion as of December 31, 2025
- R&D expenses were $987.3 million for 2025, up from $595.2 million in 2024
- Net loss was $1.1 billion for 2025, compared to $600.1 million in 2024
- 2026 GAAP operating expenses are guided to be between $1.6 and $1.7 billion
- Company is advancing five ongoing Phase 3 trials with three additional Phase 3 trials planned for 2026
Financial Impact
Increased R&D spend by $395.1 million year-over-year to $987.3 million, with 2026 operating expenses expected to grow to $1.6-$1.7 billion
Risk Factors
- High cash burn rate with $1.1 billion net loss in 2025
- Continued heavy investment with 2026 operating expenses guided at $1.6-$1.7 billion
- Clinical trial readouts may not meet expectations, particularly the pivotal RASolute 302 trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-071517 |
| Document: 0001193125-26-071517-index.html | 0001193125-26-071517 |
| Document: 0001193125-26-071517.txt | 0001193125-26-071517 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers